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The distinction between T-cell-mediated rejection (TCMR)
and other causes of kidney transplant dysfunction such as
tubular necrosis requires biopsy. Subclinical rejection (SCR),
an established risk factor for chronic allograft dysfunction,
can only be diagnosed by protocol biopsy. A specific
non-invasive biomarker to monitor immunological graft
status would facilitate diagnosis and treatment of common
transplantation-related complications. To identify possible
markers, we measured urinary mRNA levels of several
cytolytic proteins by quantitative PCR. Our cohort of 70 renal
transplant recipients had biopsy proven type I and type II
TCMR, acute tubular necrosis, SCR, calcineurin inhibitor-
toxicity, cytomegalovirus infection, and stable graft function
with normal histology. Granzyme A (GzmA) mRNA was
significantly higher in subclinical and acute cellular rejection
compared to patients with stable grafts or those with tubular
necrosis with 80% sensitivity and up to 100% specificity.
Granzyme B and perforin mRNA levels could significantly
discriminate acute rejection from stable or tubular necrosis,
but were not significantly elevated during SCR. Importantly,
only GzmA mRNA remained below detection limits from
grafts that were stable and most with tubular necrosis.
Hence, the presented data indicate that urinary GzmA
mRNA levels may entail a diagnostic non-invasive biomarker
to distinguish patients with subclinical and acute cellular
rejection from those with tubular necrosis or stable grafts.
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Subclinical1 and acute T-cell-mediated rejection (TCMR)2
are well described risk factors for late kidney graft failure.
Improving late graft outcome is currently the major clinical
challenge in transplantation. Timely detection and treatment
of rejection are important to preserve long-term graft
function. Standard diagnostics rely on serial serum creatinine
measurements followed by histopathological analysis of a
biopsy in case of increased creatinine. This strategy implies
that rejection is diagnosed when immunological injury has
led to impaired graft function. Subclinical rejection (SCR) is
a silent form of inflammation that does not lead to
immediate deterioration of function, and SCR diagnosis
therefore requires planned protocol biopsies. Nevertheless,
SCR is an important risk factor for chronic allograft
dysfunction, the leading cause of late graft loss underscoring
the importance of timely detection.3–6 Several studies have
shown that steroid treatment of SCR reduces chronic damage
and favors better outcome.7,8 However, these results are
controversial.9 Overall, studies that address long-term graft
outcome after SCR treatment are lacking. Accurate diagnosis
of both SCR and TCMR still needs biopsy. The invasiveness
of this procedure and risk for complications preclude routine
usage of repetitive biopsies. Additionally, sampling errors and
inter-observer variability complicate accurate diagnosis.10,11
To avoid biopsy, many attempts have been made to identify
non-invasive rejection markers.12 Yet, none have made their
entry into clinical practice.
The intragraft presence of granzyme B (GzmB)-positive cyto-
toxic T lymphocytes and natural killer cells is associated with
rejection.13 Urinary mRNA levels of GzmB, perforin, GzmB
inhibitor serpinB9 and FoxP3 have been put forward as para-
meters to diagnosis rejection.14–16 Sensitivity of these biomarkers
http://www.kidney-international.org o r ig ina l a r t i c l e
& 2010 International Society of Nephrology
Received 18 March 2010; revised 24 May 2010; accepted 9 June 2010;
published online 18 August 2010
Correspondence: Ajda T. Rowshani, Department of Internal Medicine and
Transplantation, Erasmus University Medical Center Rotterdam, PO Box 2040,
Rotterdam 3000 CA, The Netherlands.
E-mail: t.rowshani@erasmusmc.nl or S. Marieke van Ham, Department
of Immunopathology, Sanquin Research and Landsteiner Laboratory,
Plesmanlaan 125, Amsterdam 1066 CX, The Netherlands.
E-mail: m.vanham@sanquin.nl
7These authors contributed equally to this work.
Kidney International (2010) 78, 1033–1040 1033
to distinguish acute rejection from stable function varies between
79 and 100%, and specificity ranges from 64 to 90%, which
impedes their use in immunological graft monitoring.
Granzyme A (GzmA) and GzmB are the most abundant
cytolytic molecules of effector immune cells. However, these
granzymes target distinct cell-death pathways.17 Interestingly,
recent studies have proposed an additional function for
GzmA, triggering inflammation via induction of proinflam-
matory cytokines.18–20
In this study, we investigated the diagnostic value of
GzmA mRNA in urinary cells as a diagnostic biomarker for
subclinical and acute TCMR of kidney grafts.
RESULTS
Patient characteristics
The donor–recipient characteristics and transplantation para-
meters are detailed in Table 1. Biopsies were procured as
protocol biopsies at 6 and 12 months after transplantation,
upon clinical indication and according to the local standard
of practice. All biopsies were scored using Banff ‘05 classifica-
tion. On the basis of histopathological findings, 60 recipients
were divided into six groups. Stable group consisted of patients
with stable grafts with normal histology (n¼ 10) at the time of
sampling. Their 1-year post-transplant course was uncompli-
cated and 6 and 12 months biopsies showed normal histological
findings. Other groups consisted of patients with acute tubular
necrosis (ATN, n¼ 9), calcineurin inhibitor toxicity (n¼ 4),
SCR (n¼ 10), TCMR type-I (TCMR-I, n¼ 20), and TCMR
type-II (TCMR-II, n¼ 7). Additionally, 10 patients with
cytomegalovirus (CMV) infection were included.
Urinary GzmA mRNA expression is significantly elevated
during rejection, both subclinical and acute TCMR-I
GzmA, GzmB, perforin, and SerpinB9 mRNA levels were
measured in urinary cells (Figure 1, Supplementary Table S3
online). Gene expression was compared between stable grafts,
Table 1 | Demographic and transplantation characteristics
Characteristics Stable (n=10) ATN (n=9) CNI (n=4) TCMR-I (n=20) TCMR-II (n=7) SCR (n=10) CMV (n=10) P-value
Recipient
Age (median (year), quartiles) 44 (37–58) 57 (37–66) 52 (30–56) 53 (38–58) 47 (26–52) 51 (45–58) 46 (37–55) 0.86
Gender (% male) 70 56 50 80 57 80 70 0.80
Pretransplant CMV status (% positive) 50 78 75 60 86 50 40 0.42
Primary disease (number of patients, %) 0.50
Focal sclerosis 1 (10) 1 (11) 0 3 (15) 1 (14) 1 (10) 0
Reflux nephropathy 1 (10) 0 0 2 (10) 1 (14) 0 0
IgA nephropathy 2 (20) 0 0 6 (30) 2 (29) 3 (30) 4 (40)
Polycystic kidney disease 4 (40) 1 (11) 0 1 (5) 0 1 (10) 2 (20)
Glomerulonephritis 0 1 (11) 2 (50) 2 (10) 1 (14) 0 1 (10)
Systemic autoimmune disease 0 0 0 1 (5) 0 0 0
Diabetic nephropathy 0 0 0 1 (5) 0 0 0
Hereditary disease 0 0 0 1 (5) 0 1 (10) 0
Hypertension 0 4 (44) 2 (50) 2 (5) 2 (29) 4 (40) 1 (10)
Uncertain etiology 2 (20) 2 (22) 0 1 (5) 0 0 2 (20)
Transplantation type (%) 0.18
Deceased donor, heart beating 60 33 25 55 43 50 50
Deceased donor, non-heart beating 10 67 25 20 43 10 20
Living donor, related 20 0 0 5 14 20 10
Living donor, unrelated 10 0 50 20 0 20 20
Donor
Age (median (year), quartiles) 53 (30–57) 40 (35–59) 57 (49–60) 48 (29–57) 49 (48–61) 46 (38–54) 51 (47–58) 0.67
Gender (% male) 40 44 50 40 67 40 30 0.79
CMV status (% positive) 60 11 75 50 57 70 80 0.08
HLA mismatches total (median, quartiles) 3.0 (0.8–3.0) 3.0 (2.0–4.0) 3.0 (0.8–4.5) 3.0 (2.0–4.0) 3.0 (2.0–3.0) 2.5 (0.8–4.0) 3.0 (2.8–4.3) 0.76
Class I mismatches 2.0 (0.8–2.3) 2.0 (1.5–3.0) 2.5 (0.5–3.0) 2.0 (1.8–3.0) 2.0 (2.0–3.0) 2.0 (0.8–2.3) 2.0 (1.8–3.0) 0.85
Class II mismatches 1.0 (0.0–1.0) 1.0 (0.0–1.0) 0.5 (0.0–1.8) 1.0 (0.0–1.0) 0.0 (0.0–1.0) 0.5 (0.0–1.3) 1.0 (0.8–1.3) 0.51
Cold ischemia (median (h), quartiles) 16 (5–22) 21 (18–26) 11 (2–20) 16 (4–23) 19 (13–22) 12 (3–17) 15 (4–20) 0.19
Delayed graft function (% present) 20 78 25 40 57 20 20 0.07
Characteristics at urine sampling
GFR (median (ml per min per 1.73m2),
quartiles)a
66 (49–71) 9 (6–29) 38 (28–40) 24 (10–28) 11 (7–17) 42 (31–53) 42 (25–62) o0.01
Time of urine sampling
(median (weak after TX), quartiles)
5 (1–16) 3 (2–4) 135 (51–204) 5 (1–8) 2 (1–5) 26 (14–30) 8 (4–9) o0.01
Abbreviations: ATN, acute tubular necrosis; CMV, cytomegalovirus; CNI, calcineurin inhibitor; GFR, glomerular filtration rate; HLA, human leukocyte antigen; IgA,
immunoglobulin A; MDRD, modification of diet in renal disease; SCR, subclinical rejection; TCMR-I, T-cell-mediated rejection type I; TCMR-II, T-cell-mediated rejection type II;
TX, transplantation.
The different patient groups were compared by either Kruskal–Wallis tests for continuous variables or w2-tests for binary parameters.
aGFR in ml per min per 1.73m2 is calculated with MDRD study equation: 186 (serum creatinine (mg/dl))1.154 (age (year))0.203 (0.742, if female) (1.1210 if African Americans).36
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ATN, SCR, and TCMR-I. GzmA levels were significantly
elevated in TCMR-I compared with stable grafts (Po0.001)
and ATN (P¼ 0.001). Interestingly, similar to TCMR-I, SCR
correlated with measurable GzmA mRNA in contrast to
undetectable levels found in stable grafts (P¼ 0.001) and
ATN (P¼ 0.004) (Figure 1a).
In line with previous studies,14–16 GzmB and perforin were
significantly increased in TCMR-I as compared with stable
grafts (Po0.004) and ATN (Po0.010) (Figure 1b and c).
Relative high amounts of GzmB mRNA were found in
patients with SCR. However, GzmB mRNA could not
differentiate between SCR and either stable grafts
(P¼ 0.066) or ATN (P¼ 0.156). Perforin levels were
significantly higher in SCR than in stable grafts (P¼ 0.008).
Despite a trend, perforin expression was not significantly
elevated during SCR as compared with ATN (P¼ 0.024) after
correction for multiple testing. SerpinB9 levels were generally
high in all patients. Transcription of serpinB9 was increased
during TCMR-I compared with stable grafts, just reaching the
level of significance (P¼ 0.011, Figure 1d). Expression did
not differ significantly between any other groups.
In summary, GzmA was the only urinary biomarker that
could distinguish both SCR and TCMR-I from stable grafts
and ATN.
Transplantation-related complications can influence urinary
gene expression
To address possible assay interference of common complica-
tions after kidney transplantations, the groups were extended
with calcineurin inhibitor toxicity, TCMR-II, and CMV
infection. Expression profiles of the calcineurin inhibitor
toxicity samples were comparable with stable grafts and ATN,
with GzmA below the detection limit and variable amounts
of GzmB, perforin, and serpinB9 mRNA (Supplementary
Table S3, Supplementary Figure S1 online). The low number
of patients in this group hampers a valid statistical conclusion.
GzmA and GzmB levels found during TCMR-II (n¼ 7) were
generally lower than those found in SCR and TCMR-I, and
higher than stable grafts and ATN. None of these differences
was significant. As GzmA mRNA was undetectable in most
TCMR-II samples, this type of rejection may not be identified
using GzmA.
The immune response against CMV might influence
urinary gene expression. In our cohort, patients did not
receive prophylactic antiviral treatment. Recipients with
CMV infection showed a urinary gene-pattern comparable
with TCMR-I and SCR. GzmA and perforin levels were
significantly elevated during infection compared with stable
grafts (Po0.003) and ATN (Po0.010).
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Figure 1 |Urinary granzyme A (GzmA) mRNA expression correlates with subclinical rejection and acute T-cell-mediated rejection
(TCMR). Urine samples were collected from recipients with stable graft function (stable, n¼ 10), acute tubular necrosis (ATN, n¼ 9),
subclinical rejection (SCR, n¼ 10), and TCMR type I (TCMR-I, n¼ 20). Transcription levels of GzmA, granzyme B (GzmB), perforin, and
SerpinB9 were analyzed as described in Materials and Methods section. Horizontal lines represent medians, and asterisks refer to a
significant difference (Mann–Whitney, Po0.02 after correction for multiple testing). (a) GzmA mRNA is significantly elevated in urine of both
SCR and TCMR-I compared to stable graft function and ATN. (b) GzmB is significantly elevated during TCMR-I compared to stable and ATN.
Despite a trend towards higher levels, GzmB is not significantly elevated during SCR compared to stable and ATN. (c) Perforin transcripts are
measurable in all groups tested. Perforin levels are significantly increased during subclinical rejection (SCR) and TCMR-I as compared with
stable. (d) SerpinB9 mRNA is commonly present in urine of transplant patients at high levels (note the high upper rank depicted on the
y axis) and does not differ significantly between different groups. Transcription of this gene is significantly induced during TCMR-I compared
with stable patients.
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In conclusion, calcineurin inhibitor toxicity, a common
cause for diminished graft function, will unlikely interfere
with GzmA as a marker to diagnose rejection. CMV infection
can be a confounder, although infection is easily ruled out by
routine CMV-PCR.
Urinary GzmA mRNA is a sensitive and specific biomarker for
both subclinical and acute TCMR-I
To determine the diagnostic characteristics of GzmA, GzmB,
perforin, and serpinB9, receiver operating curve analyses
were performed (Figure 2a). Owing to undetectable GzmA in
stable grafts and in the majority of ATN samples, the
frequency of false-positive results was low. Urinary GzmA
yielded a sensitivity of 80% and a specificity of 100% when
used to distinguish both TCMR-I and SCR from stable
grafts (Figure 2b, Supplementary Table S4 online). GzmA can
discriminate SCR from ATN with a sensitivity of 80% and
specificity of 100%. Comparing TCMR-I with ATN, GzmA
reaches a sensitivity of 80% with a specificity of 78%.
The optimal cut-off values for GzmB and perforin result
in reasonable sensitivities and specificities to distinguish both
rejection types from ATN and stable grafts. However, their
implementation as diagnostic markers is limited due to over-
lapping GzmB and perforin values measured in stable grafts,
ATN, and during rejection (Supplementary Table S4 online).
Is GzmA an early biomarker for TCMR?
In 11 patients with TCMR-I, we could collect multiple urine
samples with at least one sample before biopsy. In seven of
these patients, GzmAwas detectable before biopsy. GzmB was
detectable before rejection in all patients, which is not
remarkable considering the low GzmB expression found in
70% of patients with stable grafts. After rejection treatment
and despite recovery of renal function to baseline levels,
GzmA levels became undetectable in only 55% of the
longitudinally followed up patients, but remained high or
even increased in the others. CMV-PCR remained negative in
all these cases. Unfortunately, the number of longitudinally
followed up patients and the frequency of urine sampling is
too low to determine whether GzmA precedes the rise in
serum creatinine and whether persistent GzmA levels after
treatment correlate with ongoing rejection.
Graft-infiltrating T cells express GzmA
Levels of urinary GzmA, GzmB, and perforin were signi-
ficantly correlated within one urine sample (Po0.001,
Spearman’s rank correlation coefficients ranging from 0.59
to 0.72). In contrast, serpinB9, which is expressed in
immune- and tubular epithelial cells,21 did only mildly
correlate with the other cytolytic genes. GzmA was the best
marker to distinguish rejection from stable and ATN,
suggesting selective expression of this protease. To identify
the cell source of granzymes in kidney grafts, we performed
triple immunohistochemical stainings: GzmA, GzmB, and
CD3, on biopsies corresponding to tested urine samples (n¼ 3
per group). Areas of CD3þ and CD3 cells characterized both
TCMR-I and SCR biopsies. Some of these infiltrat-
ing cells contained GzmA- and GzmB-positive granules
(Figure 3). Although rare, we could detect low numbers of
CD3-negative granzyme double-positive cells in TCMR-I
and SCR biopsies. These findings confirm that mainly T cells
but also natural killer cells are the source of urinary GzmA and
GzmB mRNA.
DISCUSSION
Our data show that urinary GzmA mRNA is a biomarker that
can distinguish both SCR and TCMR-I from stable graft
function and ATN with good sensitivity and specificity.
Comparable gene expression patterns found in SCR and
TCMR-I indicate an active ongoing inflammatory process
during SCR. In accordance with previous studies,14–16,22,23 we
found that GzmB, perforin, and serpinB9 were significantly
elevated during TCMR-I compared with stable grafts. In
contrast to GzmA, these markers did not distinguish SCR
from stable grafts or ATN.
Cellular infiltration is not invariably associated with
immediate graft dysfunction.24 SCR is a common complica-
tion, although reported frequencies vary.10,11 The strong
correlation between SCR and chronic allograft dysfunction3–6
has persuaded several researches to address the effect of SCR
treatment.7–9 Despite reported beneficial effects on graft
histology within 6 months,7,8 these studies lack to address
long-term effects of SCR treatment. SCR is in general
disregarded by publications describing non-invasive biomar-
kers to monitor immunological graft status.14–16,22,23 Schaub
et al.25 showed that urinary CXCL9 and CXCL10 levels
correlate with the extent of subclinical tubulitis, suggesting
their potential as biomarker. Also other studies have reported
urinary biomarkers that are significantly elevated during
SCR.26–28 On the basis of the presented data, urinary GzmA
mRNA entails high potential to serve as a non-invasive tool
to screen for SCR and to monitor the efficacy of treatment in
Figure 2 |Urinary granzyme A (GzmA) mRNA is a sensitive and highly specific diagnostic biomarker to distinguish subclinical and
acute cellular rejection from stable graft function and acute tubular necrosis. (a) The graphs represent receiver operating characteristic
(ROC) curves visualizing the proportion of true negative results (sensitivity) and true-positive results (specificity) using urinary mRNA levels
to discriminate between subclinical rejection (SCR) or T-cell-mediated rejection type I (TCMR-I) from respectively stable or acute tubular
necrosis (ATN). An area under the curve value of 0.5 is no better than expected by chance; a value of 1.0 reflects a perfect marker. The upper
row of ROC curves represents GzmA mRNA followed downwards by GzmB, perforin, and SerpinB9. GzmA is the most powerful diagnostic
biomarker to distinguish both types of rejection from stable and ATN as visualized by a high sensitivity and specificity (see Supplementary
Table S4 for accuracy characteristics). (b) The value of GzmA and GzmB mRNA levels in differentiating SCR or TCMR-I from stable graft
function and ATN is visualized in 2 2 contingency tables. The data represent the number of patients with, respectively, a true-positive,
false-positive, true-negative, or false-negative diagnosis of rejection based on urinary mRNA levels, as compared with biopsy findings;
the reference standard. The best cut-off points were based on the ROC curve with preference for high specificity.
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a patient-convenient manner, provided no CMV infection is
present. Correlation between rejection and expression of
cytolytic genes in blood29,30 and urine14–16 has been
addressed by others.12 Next to GzmB and perforin, urinary
serpinB9 mRNA is also elevated during TCMR-I compared
with stable grafts.23 Implementation of these parameters as
diagnostic tools is particularly hampered by overlapping
expression levels in patients with and without rejection.
GzmA, GzmB, perforin, and serpinB9 are all abundantly
expressed in cytotoxic T lymphocytes and natural killer cells,
but their expression varies between subsets.31 Once released
into the cytoplasm, granzymes activate caspase-independent
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and -dependent cascades eventually leading to target cell
death.17 Emerging evidence shows that the granule secretory
pathway may have an unexpected role in inflammation.
Secreted GzmA induced proinflammatory cytokines; in this
manner GzmA can modulate immune responses.18,19 GzmB,
on the other hand, is the prime inducer of cell death.
On the basis of our data, urinary GzmA did not correlate
with creatinine levels during rejection, nor did the other
genes tested (data not shown). Furthermore, GzmA expres-
sion was not linked to 6 months or 1-year graft survival,
severity of rejection, or effect of treatment (data not shown).
To test the value of GzmA as diagnostic biomarker, a clinical
trial with frequent urine sampling and protocol biopsies is
needed.
GzmA mRNA was undetectable in the majority of
TCMR-II samples, which was unexpected as both types of
TCMR are characterized by graft infiltrating lymphocytes. Our
findings do correspond to the lower levels of urinary perforin
and GzmB mRNA found in patients with TCMR-II compared
with TCMR-I described by Li et al.16 We observed a correlation
between measurable GzmA and presence of tubulitis in
corresponding biopsies (data not shown). GzmA containing
cells were undetectable in urine of TCMR-II with limited
tubulitis, suggesting that location of lymphocytes inside the
tubule lumen is necessary for urinary detection. Owing to the
low frequency of antibody-mediated rejection in our center, we
could not address the effect of humoral immune responses on
urinary gene expression. As TCMR and antibody-mediated
rejection have different treatment strategies, it would be very
interesting to know whether GzmA could distinguish between
these forms of rejection.
Next to rejection, kidney transplant recipients are
commonly challenged with ischemic–reperfusion injury, side
effects of immunosuppressive drugs, and CMV infection. In
our study, GzmA expression was undetectable in almost all
patients with ATN and calcineurin inhibitor toxicity. CMV
infection is characterized by high numbers of circulating
GzmBþ virus-specific T cells,32 elevated GzmB, and perforin
mRNA levels in blood and increased serum levels of soluble
serpinB9.33 Urinary GzmA mRNA was significantly elevated
during CMV infection compared with stable and ATN.
However, this is not a limit to the implementation of GzmA
as a diagnostic biomarker, as CMV can easily be ruled out by
PCR. Moreover, prophylactic antiviral therapy can prevent
infection in the early post-transplant period when the
majority of rejection episodes occur.2,4
In conclusion, urinary GzmA mRNA entails a sensitive
and specific diagnostic biomarker to distinguish SCR and
TCMR-I from stable grafts and ATN. Routine monitoring of
urinary GzmA might be a useful tool to study immunological
graft status in a reliable and patient-convenient manner.
MATERIALS AND METHODS
Kidney transplant patients
We included 70 renal transplant recipients between 2004 and 2008;
all participants gave written informed consent. All patients received
anti-interleukin-2R monoclonal antibodies (Basiliximab), predni-
sone, calcineurin inhibitor (Tacrolimus or Cyclosporin), and
mycophenolate mofetil in standard doses. TCMR was treated with
methylprednisolone 500mg for 6 consecutive days. Antithymocyte
globulin was given for steroid-resistant rejection. SCR was not
treated in this cohort.
Biopsies were taken at 6 and 12 months after transplantation,
upon clinical indication, and according to local standard of practice
and scored using the Banff ‘05 classification.34 Patients were divided
into six groups; normal histology with stable function (stable grafts:
n¼ 10), TCMR-I (n¼ 20) showing prominent tubulitis, TCMR-II
(n¼ 7) with moderate or severe intimal arteritis and tubulitis and
negative for C4D staining, ATN (n¼ 9) with no lymphocyte
infiltrates, SCR (n¼ 10), and calcineurin inhibitor toxicity (n¼ 4).
SCR was defined as histopathological TCMR without simultaneous
decline of graft function; including acute (Banff grade IA or higher,
n¼ 2) and borderline SCR (tubulitis score 1 and infiltration score
1–2, without arteritis, n¼ 8). All patients included were CMV
negative, based on CMV-PCR. Additionally, 10 patients who
experienced a CMV infection (primary n¼ 6 or reactivation
CD3 Gzm B
Gzm A Nuclei
Figure 3 | Expression and colocalization of granzyme A (GzmA), granzyme B (GzmB) by graft infiltrating T cells and natural
killer cells during rejection. Triple immunohistochemical stainings were performed to identify the source of GzmA and GzmB during
renal allograft rejection. Depicted is a biopsy with TCMR-I showing triple staining with CD3 (blue), GzmA (green), GzmB (red), nuclear
counterstaining (gray), and overlay. Many graft infiltrating cells are CD3-positive T cells containing granzymes, for example, the triple
positive cells located inside a tubulus and in the interstitium (white arrows). Granzyme-double positive, CD3-negative cells were also
present at a lower frequency, for example, the cell at the upper left. The intensity and ratio of GzmA and GzmB differed per cell.
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n¼ 4) with measurable viral replication but who remained free of
rejection were studied.
Immunohistochemistry
Expression of GzmA, GzmB, and CD3 was analyzed immunohisto-
chemically on paraffin-embedded biopsies (Supplementary Table S1
online). Nuclei were counterstained with TO-PRO3 (Invitrogen,
Carlsbad, CA, USA). Triple stainings, GzmA, GzmB, and CD3
were evaluated with a Confocal Laser Scanning Microscope (Leica
TCS-SP2, Leica Microsystems B.V., Rijswijk, The Netherlands).
Tonsil tissue was used as a positive control.
Urine sample collection
Fresh urine samples (n¼ 149, 100ml) were collected weekly, up to
10 weeks after transplantation. In case of a biopsy, an extra sample
was obtained before treatment. RNA was isolated from the urinary
cells with the GenElute Mammalian Total RNA kit (Sigma,
Zwijndrecht, The Netherlands) according to manufacturer’s instruc-
tions.
Semiquantitative real-time mRNA measurements
The isolated RNA was quantified and reverse transcribed to comple-
mentary DNA. Primers for GzmA, GzmB, perforin, and serpinB9
were developed to span exon–intron junctions (Supplementary
Table S2 online). Primers were validated on complementary DNA
of lymphokine-activated killer cells, generated by culturing isolated
peripheral bone marrow cells of healthy volunteers with 6000U/ml
interleukin-2 for 7 days. Gene expression was measured in an ABI
PRISM 7000 Sequence Detection System (Applied Biosystems,
Foster City, CA, USA) using the SYBR green method (Applied
Biosystems). Thresholds of detection were set at the lowest Ct values
within the linear amplification range. Transcript levels and relative
gene expression of mRNA were determined as described by Pfaffl.35
All results were normalized to the internal control 18S rRNA, and
are expressed relative to the expression in lymphokine-activated
killer cells.
Statistical analyses
Patient characteristics are presented as respectively median and
quartiles or percentages. Statistical analyses were performed in
GraphPad Prism (version 5, GraphPad Software, La Jolla, CA, USA)
and SPSS (version 16.0, SPSS, Chicago, IL, USA). A Kruskal–Wallis
or w2-test was used when appropriate. Experimental data are
presented as relative gene expression, median, and quartiles.
Multiple two-tailed Mann–Whitney U tests were used to compare
mRNA levels between groups. To control the false discovery rate, we
performed a Benjamini–Hochberg correction; a P-value below
0.02 was considered as significant. Receiver operating characteristic
curves were used in order to determine cut-off mRNA levels
yielding the highest specificity combined with good sensitivity.
Correlations between urinary mRNA and clinical parameters were
addressed by calculation of Spearman’s rank or Pearson’s correlation
coefficients.
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